A group of Swedish, English and Turkish researchers found that the use of metabolic activators can reduce COVID-19 recovery time by as much as 3.5 days in those patients with mild-to-moderate forms of the infection. The Swedish-Anglo study published in Advanced Science also indicated benefits associated with inflammation level of the liver as revealed by inflammatory markers. Led by investigators at Science for Life Laboratory at KTH Royal Institute of Technology in Stockholm, the study team collaborated with another Swedish group called the Sahlgrenska Academy based in Gothenburg as well as King’s College, London, where a Phase 3 clinical trial reveals that patients with mild-to-moderate COVID-19—that is, those cases representing the overwhelming majority of COVID-19 cases—who also received standard of care, experienced overall a 3.5-day reduction in recovery time when receiving the combination of metabolic activators, nicotinamide riboside (NR), L-serine, N-acetyl-L-cysteine (NAC), and L-carnitine tartrate. All four of these activators are aimed at improving mitochondrial function. These results build upon the positive findings of Phase 2 clinical data, report the authors in a recent press release. The Phase 3 study was actually conducted at the Umraniye Teaching and Research Hospital, University of Health Sciences in Istanbul. Now thanks to these results, the combination therapy was submitted for marketing authorization in Turkey.
Trial Sites in Turkey Reveal Potential of this Approach
Through a randomized, placebo-controlled, double-blind phase three clinical trial, 309 outpatients at Umraniye Teaching and Research Hospital, University of Health Sciences in Istanbul, Turkey, were randomly assigned on a 3:1 basis to receive the metabolic activators or placebo. Patients received the combined activators or placebo twice a day for 14 days and clinical status was evaluated through daily telephone check-ins.
“Our phase three data shows that metabolic activators significantly improve the recovery, liver health, and markers of inflammation of patients with COVID-19,” says the study’s lead author, Adil Mardinoglu, professor at KTH and Kings College and research fellow at Science for Life Laboratory.
“Dysfunctional mitochondria have been implicated in worsened progression for Covid-19, and we are pleased to find that the combination of these metabolic activators helps to remedy the stress put on the body of an infected patient.”
Study Partnerships Lead to Submission of the Drug
The study was conducted in partnership with Stockholm-based ScandiBio Therapeutics AB and California-based ChromaDex (NASDAQ:CDXC), which provided one of the four ingredients (nicotinamide riboside) through the ChromaDex External Research Program (CERP). Together with the strategic partner Viscoran (Turkey), a submission for drug approval has been submitted to the Ministry of Health in Turkey.
Adil Mardinoglu, professor at KTH and Kings College and research fellow at Science for Life Laboratory.